Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.

Summary

The purpose of this study is to determine if either of two doses of EMD 273066 when given with a low dose of cyclophosphamide will result in a second time to progression that is as long or longer than the first time to progression

Timeline

Start

2006-12-31

Primary completion

2008-05-31

Completion

2008-05-31

Outcome

Outcome not reported

Stopped: “Th trial got cancelled and no subjects signed informed consent form (ICF); study design not appropriate any longer.”

Drugs

Indications